lamotrigine has been researched along with Affective Disorders in 42 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to evaluate the effectiveness of lamotrigine in reducing affective instability in borderline personality disorder (BPD)." | 9.14 | A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. ( Bieri, KA; Reich, DB; Zanarini, MC, 2009) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 8.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| "Recent published data and treatment guidelines have created uncertainty about the use of lamotrigine in affective disorders, especially in acute bipolar depression." | 8.87 | Lamotrigine: when and where does it act in affective disorders? A systematic review. ( Amann, B; Born, C; Crespo, JM; McKenna, P; Pomarol-Clotet, E, 2011) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 8.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| "Lamotrigine is an anticonvulsant drug with good efficacy and safety in the treatment of epilepsy." | 8.82 | Lamotrigine in mood disorders. ( Green, B, 2003) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 8.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Lamotrigine is widely used for mood disorders including bipolar disorder and major depression, but its therapeutic levels have yet to be determined." | 7.80 | Therapeutic window of lamotrigine for mood disorders: a naturalistic retrospective study. ( Hatano, K; Itoh, H; Kamei, K; Katayama, Y; Kodama, K; Kohno, K; Makino, M; Mizokami, Y; Terao, T, 2014) |
| "Lamotrigine has been demonstrated to be effective as both an antiepileptic drug and a mood stabiliser." | 6.49 | Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons? ( Dodd, S; Horgan, D; Vajda, FJ, 2013) |
| " Questions concerned the frequency of prescribing depending on the mood disorder, the frequency of plasma levels, therapeutic monitoring, dosage adjustment and the limitation represented by dermatological risk." | 5.91 | Lamotrigine in mood disorders: Flash survey on prescribing habits and blood tests practices. ( Bloch, V; Chouchana, M; Delage, C; Etain, B; Fontan, JE; Smati, J, 2023) |
| "Lamotrigine (LTG) is an antiepileptic drug that is also effective in the treatment of certain psychiatric disorders." | 5.31 | Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders. ( Aroniadou-Anderjaska, V; Braga, MF; Li, H; Post, RM, 2002) |
| "The objective of this study was to evaluate the effectiveness of lamotrigine in reducing affective instability in borderline personality disorder (BPD)." | 5.14 | A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. ( Bieri, KA; Reich, DB; Zanarini, MC, 2009) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 4.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| "Recent published data and treatment guidelines have created uncertainty about the use of lamotrigine in affective disorders, especially in acute bipolar depression." | 4.87 | Lamotrigine: when and where does it act in affective disorders? A systematic review. ( Amann, B; Born, C; Crespo, JM; McKenna, P; Pomarol-Clotet, E, 2011) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 4.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| "A systematic search was carried out of electronic databases, reference books and other sources for original research studies which examined the effects of commonly used mood stabilizers (sodium valproate, carbamazepine, lamotrigine and lithium carbonate) on pregnancy outcomes." | 4.86 | Mood stabilizers in pregnancy: a systematic review. ( Buist, A; Galbally, M; Roberts, M, 2010) |
| " As the result of the detailed analysis of the literature the author recommends lamotrigine, carbamazepine and oxcarbazepine as first choice antiepileptic drug for epileptic patients suffering from depressive disorder, too." | 4.84 | [Effects of antiepileptic drugs on mood of people with epilepsy]. ( Rajna, P, 2007) |
| "Lamotrigine is an anticonvulsant drug with good efficacy and safety in the treatment of epilepsy." | 4.82 | Lamotrigine in mood disorders. ( Green, B, 2003) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 4.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Lamotrigine is widely used for mood disorders including bipolar disorder and major depression, but its therapeutic levels have yet to be determined." | 3.80 | Therapeutic window of lamotrigine for mood disorders: a naturalistic retrospective study. ( Hatano, K; Itoh, H; Kamei, K; Katayama, Y; Kodama, K; Kohno, K; Makino, M; Mizokami, Y; Terao, T, 2014) |
| "Patients with major affective disorders are more likely to complete suicide than patients in any other medical group." | 3.79 | Anticonvulsant therapy and suicide risk in affective disorders. ( Goodwin, FK, 1999) |
| "Pharmacotherapy for mood disorders during pregnancy is often complicated by pregnancy-related pharmacokinetic changes and the need for dose adjustments." | 2.50 | Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. ( Byatt, N; Deligiannidis, KM; Freeman, MP, 2014) |
| "Lamotrigine has been demonstrated to be effective as both an antiepileptic drug and a mood stabiliser." | 2.49 | Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons? ( Dodd, S; Horgan, D; Vajda, FJ, 2013) |
| " Questions concerned the frequency of prescribing depending on the mood disorder, the frequency of plasma levels, therapeutic monitoring, dosage adjustment and the limitation represented by dermatological risk." | 1.91 | Lamotrigine in mood disorders: Flash survey on prescribing habits and blood tests practices. ( Bloch, V; Chouchana, M; Delage, C; Etain, B; Fontan, JE; Smati, J, 2023) |
| "Topiramate was more likely prescribed for those with comorbid headache or migraine (incident: 335 of 1251 [26." | 1.51 | Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy. ( Faught, E; Fishman, J; Kalilani, L; Kim, H; Thurman, DJ, 2019) |
| "Lamotrigine (LTG) was less successful in those with a parental history of mood disorders or in BP-I compared to BP-II disorder." | 1.43 | Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. ( Altshuler, LL; Frye, MA; Grunze, H; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Nolen, WA; Post, RM; Rowe, M; Suppes, T, 2016) |
| "For the management of bipolar depression, new data support quetiapine monotherapy as a first-line option." | 1.33 | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. ( Beaulieu, S; Kennedy, SH; MacQueen, G; McIntyre, RS; O'Donovan, C; Parikh, SV; Sharma, V; Yatham, LN, 2006) |
| "Lamotrigine is an anticonvulsant with an efficacy profile in psychiatric disorders different from those of valproate, carbamazepine and gabapentine." | 1.31 | [Lamotrigine in the treatment of mental disorders]. ( Fladvad, T; Malt, UF, 2001) |
| "Lamotrigine (LTG) is an antiepileptic drug that is also effective in the treatment of certain psychiatric disorders." | 1.31 | Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders. ( Aroniadou-Anderjaska, V; Braga, MF; Li, H; Post, RM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (9.52) | 18.2507 |
| 2000's | 18 (42.86) | 29.6817 |
| 2010's | 17 (40.48) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, AM | 1 |
| Weinshilboum, RM | 1 |
| Frye, MA | 6 |
| Biernacka, JM | 1 |
| Chmiel, I | 1 |
| Chouchana, M | 1 |
| Smati, J | 1 |
| Bloch, V | 1 |
| Fontan, JE | 1 |
| Etain, B | 1 |
| Delage, C | 1 |
| Pariente, G | 1 |
| Leibson, T | 1 |
| Shulman, T | 1 |
| Adams-Webber, T | 1 |
| Barzilay, E | 1 |
| Nulman, I | 1 |
| Kim, H | 1 |
| Faught, E | 1 |
| Thurman, DJ | 1 |
| Fishman, J | 1 |
| Kalilani, L | 1 |
| Abe, Y | 1 |
| Yasugawa, S | 1 |
| Miyamoto, K | 1 |
| Terao, T | 2 |
| Öncü, B | 1 |
| Er, O | 1 |
| Çolak, B | 1 |
| Nutt, DJ | 1 |
| Marrero-Gonzalez, PC | 1 |
| Ruano, OL | 1 |
| Catalano, G | 1 |
| Catalano, MC | 1 |
| Deligiannidis, KM | 1 |
| Byatt, N | 1 |
| Freeman, MP | 1 |
| Katayama, Y | 1 |
| Kamei, K | 1 |
| Hatano, K | 1 |
| Kohno, K | 1 |
| Makino, M | 1 |
| Mizokami, Y | 1 |
| Kodama, K | 1 |
| Itoh, H | 1 |
| Bowen, RC | 1 |
| Balbuena, L | 1 |
| Baetz, M | 1 |
| Mauer, S | 1 |
| Alahmari, R | 1 |
| Vöhringer, PA | 1 |
| Vergne, DE | 1 |
| Lövdahl, H | 1 |
| Correa, E | 1 |
| Patkar, A | 1 |
| Pae, C | 1 |
| Strejilevich, S | 1 |
| Dalley, S | 1 |
| Ghaemi, SN | 1 |
| Post, RM | 6 |
| Leverich, GS | 4 |
| Kupka, R | 1 |
| Keck, PE | 2 |
| McElroy, SL | 2 |
| Altshuler, LL | 2 |
| Rowe, M | 1 |
| Grunze, H | 2 |
| Suppes, T | 3 |
| Nolen, WA | 2 |
| Sümegi, A | 1 |
| Reich, DB | 1 |
| Zanarini, MC | 1 |
| Bieri, KA | 1 |
| Amann, B | 1 |
| Born, C | 1 |
| Crespo, JM | 1 |
| Pomarol-Clotet, E | 1 |
| McKenna, P | 1 |
| Galbally, M | 1 |
| Roberts, M | 1 |
| Buist, A | 1 |
| Sharma, RC | 1 |
| Weiss, SR | 1 |
| Gazdag, G | 1 |
| Takács, R | 1 |
| Ungvari, GS | 1 |
| Tanahashi, S | 1 |
| Yamamura, S | 1 |
| Nakagawa, M | 1 |
| Motomura, E | 1 |
| Okada, M | 1 |
| Vajda, FJ | 1 |
| Dodd, S | 1 |
| Horgan, D | 1 |
| Green, B | 1 |
| Yatham, LN | 3 |
| Kennedy, SH | 2 |
| O'Donovan, C | 2 |
| Parikh, S | 1 |
| MacQueen, G | 2 |
| McIntyre, R | 1 |
| Sharma, V | 2 |
| Silverstone, P | 1 |
| Alda, M | 1 |
| Baruch, P | 1 |
| Beaulieu, S | 2 |
| Daigneault, A | 1 |
| Milev, R | 1 |
| Young, LT | 1 |
| Ravindran, A | 1 |
| Schaffer, A | 1 |
| Connolly, M | 1 |
| Gorman, CP | 1 |
| Selai, C | 1 |
| Bannister, D | 1 |
| Trimble, M | 1 |
| Meador, KJ | 1 |
| Loring, DW | 1 |
| Vahle, VJ | 1 |
| Ray, PG | 1 |
| Werz, MA | 1 |
| Fessler, AJ | 1 |
| Ogrocki, P | 1 |
| Schoenberg, MR | 1 |
| Miller, JM | 1 |
| Kustra, RP | 1 |
| Parikh, SV | 1 |
| McIntyre, RS | 1 |
| Calabrese, JR | 1 |
| Bowden, CL | 2 |
| Ketter, TA | 3 |
| Adams, BE | 1 |
| Thompson, TR | 1 |
| Krupitsky, EM | 1 |
| Rudenko, AA | 1 |
| Burakov, AM | 1 |
| Slavina, TY | 1 |
| Grinenko, AA | 1 |
| Pittman, B | 1 |
| Gueorguieva, R | 1 |
| Petrakis, IL | 1 |
| Zvartau, EE | 1 |
| Krystal, JH | 1 |
| Shen, YC | 1 |
| Kelly, DI | 1 |
| Mintz, J | 1 |
| Luckenbaugh, DA | 3 |
| Kupka, RW | 1 |
| Rajna, P | 1 |
| Gillham, R | 1 |
| Baker, G | 1 |
| Thompson, P | 1 |
| Birbeck, K | 1 |
| McGuire, A | 1 |
| Tomlinson, L | 1 |
| Eckersley, L | 1 |
| Silveira, C | 1 |
| Brown, S | 1 |
| Goodwin, FK | 1 |
| Kimbrell, TA | 1 |
| Dunn, RT | 1 |
| Speer, AM | 2 |
| Osuch, EA | 2 |
| Cora-Ocatelli, G | 1 |
| Malt, UF | 1 |
| Fladvad, T | 1 |
| Goldberg, JF | 1 |
| Burdick, KE | 1 |
| Obrocea, GV | 1 |
| Dunn, RM | 1 |
| Jajodia, K | 1 |
| Braga, MF | 1 |
| Aroniadou-Anderjaska, V | 1 |
| Li, H | 1 |
| Hurley, SC | 1 |
| Sachs, GS | 1 |
| Cosgrove, VE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Prophylactic Management of Lamotrigine for Bipolar Disorder in Pregnant Women[NCT03774641] | 20 participants (Anticipated) | Observational | 2018-12-03 | Recruiting | |||
| A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study[NCT00400088] | Phase 3 | 2 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Recruitment difficulties) | ||
| Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety[NCT00590265] | 50 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | |||
| Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial[NCT01054599] | 29 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| Cognitive Effects of Treatment of Interictal Discharges[NCT00916149] | 31 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| A Randomized, Pilot Study to Evaluate the Tolerability of OnabotulinumtoxinA Plus Topiramate vs. OnabotulinumtoxinA Plus Placebo and Long Term Effect of Treatment on Cognitive Efficiency and Continuation of Care[NCT01700387] | Phase 4 | 20 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Evaluation of Lamotrigine (Lamictal® (Registered Trademark)) Monotherapy and Gabapentin (Neurontin® (Registered Trademark)) Monotherapy in the Treatment of Mood Disorders[NCT00001482] | Phase 2 | 60 participants | Interventional | 1995-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
SRT-CLTR (range 0-72; higher scores indicate better memory), and 7-24 Spatial Memory Test (range 0-35; scores are summed across the 5 learning trials, with higher scores indicating better memory) scores will be assessed across the first (baseline) and third (post-open label memantine) testing sessions. These measures are considered to be scores on a scale, rather than standard units. The hypothesis was that subjects randomized to memantine would demonstrate sustained improvement from baseline, while the placebo group would demonstrate improvements after taking open label memantine (compared to baseline). (NCT01054599)
Timeframe: 26 weeks
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| SRT CLTR Baseline | SRT CLTR Post-Open Label | 7-24 Total Learning Baseline | 7-24 Total Learning Post-Open Label | |
| Memantine | 32.67 | 40.33 | 30.33 | 31.67 |
| Sugar Pill | 22.71 | 40.29 | 28.14 | 32.43 |
Change scores from pre- to post-treatment/placebo were calculated for the primary outcome measures, the Selective Reminding Test Continuous Long-Term Retrieval (range 0-72; higher scores indicate better memory) and 7-24 Spatial Recall Test Total Learning (range 0-35; total correct across 5 learning trials are summed, with higher scores indicating better memory) scores. These measures are scores on a scale, rather than representing standard units. (NCT01054599)
Timeframe: 13 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| 7-24 Spatial Recall Tests Learning Change Score | SRT Continuous Long-Term Retrieval Change Score | |
| Memantine | 1.00 | 4.38 |
| Sugar Pill | 1.78 | 8.11 |
This descriptive analysis examined the change in interictal discharge rates pre to post-treatment with levetiracetam in subjects with epilepsy and with no treatment in healthy controls. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | IEDs/hour (Mean) |
|---|---|
| No Treatment | -28.8 |
| Levetiracetam | .54 |
Change in Adverse Events Profile score (scores range from 19-76; higher scores indicate greater side effects) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | -1.27 |
| Levetiracetam | 1 |
Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall score (the score ranges from 0-6, reflecting the number of shapes recalled after a 25 minute delay) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .36 |
| Levetiracetam | .33 |
Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Learning score (the score ranges from 0-6, reflecting the number of shapes recalled on the initial learning trial) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .45 |
| Levetiracetam | .33 |
Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Total Learning score (the score is summed across 3 learning trials, score range 0-18, reflecting the total number of shapes recalled) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 1.09 |
| Levetiracetam | .17 |
Change in Choice Accuracy Score (indicate if red or blue stimulus; accuracy 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | .02 |
| Levetiracetam | .1 |
Change in Choice Reaction Time Score, with reaction time measured in seconds (indicate if red or blue stimulus; lower reaction time suggests better performance) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | 34.96 |
| Levetiracetam | .45 |
Change in Continuous Performance Test Score - Accuracy (CPT; score ranges from 0-100% correct) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | -0.01 |
| Levetiracetam | .01 |
Change in Continuous Performance Test Score - Reaction Time, measured in seconds (CPT RT; less time reflects better performance) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | 1.04 |
| Levetiracetam | -11.33 |
Change in California Verbal Learning Test (CVLT) Long Delay Recall score (the score ranges from 0-16, reflecting the number of words recalled) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 1.55 |
| Levetiracetam | 2.67 |
Change in California Verbal Learning Test (CVLT) Short Delay Recall Score (the score ranges from 0-16, reflecting the number of words recalled) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 1.27 |
| Levetiracetam | -0.4 |
Change in California Verbal Learning Test (CVLT) Total Learning Score (the total learning score is summed across 5 learning trials, range 0-80). Higher scores indicate better memory. Scores on the CVLT reflect the number of words recalled. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 8.09 |
| Levetiracetam | 5.5 |
Change in California Verbal Learning Test (CVLT) Trial 1 learning score (range 0-16; higher score indicates better memory) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 2.45 |
| Levetiracetam | 2.5 |
Change in Design Fluency score (Score range: lowest score = 0; there is no upper limit. A higher score reflects more designs generated, hence better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 2.8 |
| Levetiracetam | .83 |
Change in Digit Span score (score ranges from 0-30; higher scores indicate better performance). Scores indicate the number of digit sequences correctly recalled, forwards and backwards. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .73 |
| Levetiracetam | -.33 |
Change in Digit Symbol Score (The score is the number of items completed. A higher score reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 3.2 |
| Levetiracetam | 1.5 |
Change in Facial Recognition Accuracy Score (accuracy ranges from 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | .01 |
| Levetiracetam | .03 |
Change in Facial Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -66.76 |
| Levetiracetam | .61 |
Change in Grooved Pegboard Score (The score is the time for completion. A lower score reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -4.73 |
| Levetiracetam | -4.36 |
Change in Letter-Number Sequencing score (LNS; score ranges from 0-21; higher scores indicate better performance). The score reflects the number of items that the subject can correctly recall and place in proper alphabetical and numerical sequence. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | .18 |
| Levetiracetam | -0.5 |
Change in Neurological Disorders Depression Inventory for Epilepsy (NDDIE) score (scores range from 0-24; higher scores indicate greater depressive symptoms) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 0.18 |
| Levetiracetam | 1.5 |
Change in Non-verbal Working Memory Accuracy Score (accuracy ranges from 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | -.01 |
| Levetiracetam | 0 |
Change in Non-verbal Working Memory Reaction Time Score (indicates processing speed, with reaction time measured in seconds) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -31.99 |
| Levetiracetam | -25.54 |
Change in Quality of Life Inventory in Epilepsy-89 score (QOLIE; score ranges from 0-100; higher scores reflect better quality of life) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Levetiracetam | 19.6 |
Change in Spatial Span score (score ranges from 0-32; higher scores indicate better performance). Scores indicate the number of spatial sequences correctly recalled, forwards and backwards. (NCT00916149)
Timeframe: 1 and 11 Weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .36 |
| Levetiracetam | -1.67 |
Change in Stroop score (The score is the time for completion in seconds; less time reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | .98 |
| Levetiracetam | -7.3 |
Change in Trails Test score (The score is the time for completion in seconds. A lower score reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -9.51 |
| Levetiracetam | 11.29 |
Change in Verbal Fluency score (Score range: lowest score = 0, with no upper limit, reflecting total number of words generated. Higher scores indicate better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | -1.55 |
| Levetiracetam | -.83 |
Change in Verbal Recognition Accuracy Score (accuracy ranges from 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | .02 |
| Levetiracetam | .14 |
Change in Verbal Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | 2.98 |
| Levetiracetam | -6.1 |
Change in Verbal Working Memory Accuracy Score (range 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | 0 |
| Levetiracetam | -.02 |
Change in Verbal Working Memory Reaction Time Score, with reaction time measured in seconds (indicates processing speed) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -54.76 |
| Levetiracetam | -9.36 |
(NCT01700387)
Timeframe: 13 Months (Visit 1 to Visit 6)
| Intervention | Adverse Events (Mean) |
|---|---|
| OnabotulinumtoxinA + Topiramate | 8.60 |
| OnabotulinumtoxinA + Placebo | 4.60 |
The Headache Impact Test (HIT-6) is a tool used to measure the impact headaches have on an individual's ability to function on the job, at school, at home and in social situations. The HIT-6 score range is from 36 to 78 with higher scores indicating greater impact (worse outcome). (NCT01700387)
Timeframe: Collected on Visit 2 (Day 29), 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 66.50 | 59.9 | 60.44 | 58.71 | 54.17 |
| OnabotulinumtoxinA + Topiramate | 66.40 | 61.89 | 54.5 | 52.83 | 52.57 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 21.74 | 8.59 | 12.72 | 24.75 |
| OnabotulinumtoxinA + Topiramate | 19.06 | 15.04 | 18.49 | 40.86 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 17.74 | 16.43 | 28.61 | 29.44 |
| OnabotulinumtoxinA + Topiramate | -11.23 | -22.90 | -23.81 | 1.52 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 1.13 | 4.39 | 18.81 | 2.2 |
| OnabotulinumtoxinA + Topiramate | -15.66 | -1.20 | -3.96 | -6.99 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 14.22 | 4.76 | -4.17 | 2.31 |
| OnabotulinumtoxinA + Topiramate | -8.90 | -3.20 | -3.87 | -3.16 |
Number of Headache Days reported in 30-day Baseline Period and Treatment Period Months 1-12 (NCT01700387)
Timeframe: Baseline and Months 1-12
| Intervention | Headache days (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | |
| OnabotulinumtoxinA + Placebo | 23.77 | 21.67 | 17.54 | 18.37 | 14.39 | 13.47 | 16.58 | 12.54 | 11.5 | 9.96 | 8.02 | 8.51 | 8.06 |
| OnabotulinumtoxinA + Topiramate | 22.95 | 18.41 | 16.50 | 16.83 | 15.74 | 11.34 | 15.18 | 12.64 | 12.36 | 12.02 | 6.93 | 8.36 | 7.51 |
Score on Physician Global Impression of Change at Visits 3-6 (Day 113 and 365). Likert scale ranging from 1-7, where 1 = extremely worse and 7 = extremely better. (NCT01700387)
Timeframe: Collected on Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 5.30 | 5.89 | 5.83 | 5.83 |
| OnabotulinumtoxinA + Topiramate | 5.25 | 5.40 | 6.67 | 6.83 |
Count of subject attrition following randomization and reason for attrition (Consent withdrawn, Withdrawn due to adverse event, Lost to follow up) (NCT01700387)
Timeframe: Collected on Visit 2 (Day 29) through Visit 6 (Day 365)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Consent Withdrawn | Withdrawn Due to Adverse Event | Lost to Follow Up | |
| OnabotulinumtoxinA + Placebo | 2 | 1 | 1 |
| OnabotulinumtoxinA + Topiramate | 1 | 1 | 2 |
Subject estimation of compliance with daily study drug during the study period. Compliance ranges from 0% to 100% with higher percentages indicating greater compliance with study drug. (NCT01700387)
Timeframe: Collected on Visit 2 (Day 29), 3 (Day 113), Visit 4 (Day 197), and Visit 5 (281)
| Intervention | percentage of compliance (Mean) | |||
|---|---|---|---|---|
| Visit 2 | Visit 3 | Visit 4 | Visit 5 | |
| OnabotulinumtoxinA + Placebo | 99.73 | 99.73 | 97.65 | 99.63 |
| OnabotulinumtoxinA + Topiramate | 100 | 99.84 | 99.55 | 98.69 |
Score on Subject Global Impression of Change at Visits 3-6 (Day 113 and 365). Likert scale ranging from 1-7, where 1 = extremely worse and 7 = extremely better. (NCT01700387)
Timeframe: Collected on Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 5.30 | 5.77 | 6.17 | 6.00 |
| OnabotulinumtoxinA + Topiramate | 5.38 | 6.33 | 6.66 | 7.00 |
The Controlled Oral Word Association Test (COWAT) is a measure of verbal fluency. Raw COWAT scores have a lower bound of 0 with no upper bound. Higher scores indicate better verbal fluency. COWAT score percent change from baseline will be reported. Positive change scores represent better verbal fluency compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113) through Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | -3.50 | -8.93 | 1.48 | -4.99 |
| OnabotulinumtoxinA + Topiramate | -17.06 | -17.93 | -12.63 | -5.05 |
The Migraine-Specific Quality of Life Questionnaire (MSQ) is a scale that measures the impact of migraine across three aspects: role function-restrictive (RR), role function-preventive (RP), and emotional function (EF). Possible scores on each sub-scale range from a 0 to 100 scale such that higher scores indicate better quality of life. (NCT01700387)
Timeframe: Baseline, Months: 3, 6, 9 and 12
| Intervention | score on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Role Function-Restrictive - Baseline | Role Function-Restrictive - Month 3 | Role Function-Restrictive - Month 6 | Role Function-Restrictive - Month 9 | Role Function-Restrictive - Month 12 | Role Function-Preventive - Baseline | Role Function-Preventive - Month 3 | Role Function-Preventive - Month 6 | Role Function-Preventive - Month 9 | Role Function-Preventive - Month 12 | Emotional Function - Baseline | Emotional Function - Month 3 | Emotional Function - Month 6 | Emotional Function - Month 9 | Emotional Function - Month 12 | |
| OnabotulinumtoxinA + Placebo | 29.71 | 56.29 | 59.37 | 60.41 | 72.38 | 46.50 | 65.00 | 72.22 | 72.86 | 80.83 | 22.67 | 56.67 | 56.30 | 70.48 | 78.89 |
| OnabotulinumtoxinA + Topiramate | 32.14 | 56.51 | 77.14 | 79.52 | 81.90 | 56.50 | 72.78 | 90.00 | 88.33 | 96.67 | 39.33 | 57.78 | 88.89 | 92.22 | 95.56 |
18 reviews available for lamotrigine and Affective Disorders
| Article | Year |
|---|---|
Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know?
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Humans; La | 2021 |
Ketogenic diet in therapy of bipolar affective disorder - case report and literature review.
Topics: Anticonvulsants; Bipolar Disorder; Diet, Ketogenic; Humans; Lamotrigine; Male; Mood Disorders; Queti | 2022 |
Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant, Newbo | 2017 |
Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.
Topics: Antidepressive Agents; Carbamazepine; Drug Monitoring; Female; Humans; Lamotrigine; Mood Disorders; | 2014 |
[Mood stabilizers--past, present and future].
Topics: Affect; Antimanic Agents; Bipolar Disorder; Calcium; Carbamazepine; Depressive Disorder; gamma-Amino | 2008 |
Lamotrigine: when and where does it act in affective disorders? A systematic review.
Topics: Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Humans; Lamotrigine; Mood Disorders; T | 2011 |
Mood stabilizers in pregnancy: a systematic review.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Carbamazepin | 2010 |
Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders.
Topics: Amygdala; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Drug Resistance; Drug Tolerance | 2011 |
[The optimal combination of ECT with pharmacotherapy].
Topics: Affect; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tric | 2011 |
Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Epilepsy; Female; Humans; Lamotr | 2013 |
Lamotrigine in mood disorders.
Topics: Analgesics; Animals; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Clinical Trials as To | 2003 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
[Effects of antiepileptic drugs on mood of people with epilepsy].
Topics: Affect; Anticonvulsants; Antidepressive Agents; Carbamazepine; Depressive Disorder; Epilepsy; Fructo | 2007 |
New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine.
Topics: Affect; Anticonvulsants; Humans; Lamotrigine; Mood Disorders; Triazines; Valproic Acid | 1998 |
Anticonvulsant therapy and suicide risk in affective disorders.
Topics: Amitriptyline; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Female; Follow | 1999 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
Lamotrigine update and its use in mood disorders.
Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; | 2002 |
Bipolar disorder: current treatments and new strategies.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Fructose; Gabapent | 1998 |
7 trials available for lamotrigine and Affective Disorders
| Article | Year |
|---|---|
A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder.
Topics: Adult; Antimanic Agents; Borderline Personality Disorder; Double-Blind Method; Female; Humans; Lamot | 2009 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam.
Topics: Adult; Alcoholism; Arousal; Autonomic Nervous System; Depression; Diazepam; Excitatory Amino Acid An | 2007 |
Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments.
Topics: Adolescent; Adult; Affect; Aging; Anticonvulsants; Behavior; Carbamazepine; Cognition Disorders; Dou | 1996 |
Anticonvulsant therapy and suicide risk in affective disorders.
Topics: Amitriptyline; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Female; Follow | 1999 |
A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders.
Topics: Acetates; Adult; Amines; Antimanic Agents; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-B | 2000 |
Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders.
Topics: Acetates; Adult; Aged; Amines; Antidepressive Agents; Cross-Over Studies; Cross-Sectional Studies; C | 2002 |
18 other studies available for lamotrigine and Affective Disorders
| Article | Year |
|---|---|
Lamotrigine in mood disorders: Flash survey on prescribing habits and blood tests practices.
Topics: Anticonvulsants; Humans; Lamotrigine; Mood Disorders; Surveys and Questionnaires; Triazines | 2023 |
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Anxiety Disorders; Comorbidity; Dissociative Disorders; Epilepsi | 2019 |
Valproate as a risk factor for lamotrigine discontinuation.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Drug Therapy, Combination; Female; | 2013 |
Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Female; Humans; Lamotrigine; Male; | 2014 |
Dystonia associated with lamotrigine therapy: a case report and review of the literature.
Topics: Antidepressive Agents; Basal Ganglia Diseases; Dystonia; Humans; Lamotrigine; Male; Middle Aged; Moo | 2014 |
Therapeutic window of lamotrigine for mood disorders: a naturalistic retrospective study.
Topics: Adult; Aged; Analysis of Variance; Drug Monitoring; Excitatory Amino Acid Antagonists; Female; Human | 2014 |
Lamotrigine reduces affective instability in depressed patients with mixed mood and anxiety disorders.
Topics: Adult; Anxiety Disorders; Depressive Disorder; Female; Humans; Lamotrigine; Male; Middle Aged; Mood | 2014 |
International prescribing patterns for mood illness: the International Mood Network (IMN).
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Asia; Bipolar Disorder; Carbamazepine | 2014 |
Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disor | 2016 |
Lamotrigine effective in postmenstrual dysphoric disorder: a case report.
Topics: Antimanic Agents; Female; Follow-Up Studies; Humans; Lamotrigine; Menstruation Disturbances; Mood Di | 2010 |
Effect of lamotrigine and carbamazepine on corticotropin-releasing factor-associated serotonergic transmission in rat dorsal raphe nucleus.
Topics: Animals; Anticonvulsants; Carbamazepine; Corticotropin-Releasing Hormone; Dose-Response Relationship | 2012 |
Antiepileptic drugs and the regulation of mood and quality of life (QOL): the evidence from epilepsy.
Topics: Affect; Anticonvulsants; Carbamazepine; Epilepsy; Health Status; Humans; Lamotrigine; Mood Disorders | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Bipo | 2006 |
Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Comorbidity; Depression; Humans; Incidence; Lamotrigine; | 2006 |
Lamotrigine in motor and mood symptoms of Huntington's disease.
Topics: Antimanic Agents; Atrophy; Caudate Nucleus; Cerebral Cortex; Chorea; Female; Humans; Huntington Dise | 2008 |
Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Databases, Factual; Depression; Dib | 2007 |
[Lamotrigine in the treatment of mental disorders].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Depression; Femal | 2001 |
Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders.
Topics: Amygdala; Animals; Anticonvulsants; Excitatory Amino Acid Antagonists; GABA-A Receptor Antagonists; | 2002 |